WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of PFIZER INC (PFE)

Name PFIZER INC
Year low 16.63
Year High 23.30
Symbol PFE
Last trade 22.62
Percentage change 0.35
Volume 10,545,420
Media Volume (3m) 38,188,900
PE Ratio 18.28
EPS 1.233
Market Cap 169400
Media fatt 65792
Trend fatt trend fatt graph for PFIZER INC
Media net income 9294
Trend net income trend net income for PFIZER INC
P / E P / E graph for PFIZER INC - 11 points 11
EPS EPS graph for PFIZER INC - 14 points 14
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for PFIZER INC - 2 points 2
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for PFIZER INC - 2 points 2
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for PFIZER INC - 11 points 11
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for PFIZER INC - 8 points 8
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for PFIZER INC - 3 points 3
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for PFIZER INC - 2 points 2
NET INC1/NET INC3 net inc1/net inc3 graph for PFIZER INC - 0 points 0
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for PFIZER INC - 3 points 3
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for PFIZER INC - 0 points 0
. . graph for PFIZER INC - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for PFIZER INC - 0 points 0
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for PFIZER INC - 0 points 0
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for PFIZER INC - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for PFIZER INC - 3 points 3
. . graph for PFIZER INC - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for PFIZER INC - 0 points 0
SINTESE 59

GRAPHS

max price logarithm graph for PFIZER INC based on no conditions max volume linear graph for PFIZER INC based on no conditions

News

FDA staff shoots down Pfizer rare disease drug (May 22 - reuters) UPDATE 1-US FDA staff shoots down Pfizer rare disease drug (May 22 - reuters) US FDA staff shoot down Pfizer rare disease drug (May 22 - reuters) Pfizer Invites Public to View and Listen to Webcast of June 3 Pfizer Analyst and Investor Meeting at ASCO (May 22 - reuters) Will the Dow Break Its Losing Streak? (May 21 - reuters) Shorts Are Piling Into These Stocks. Should You Be Worried? (May 21 - reuters) Why Johnson & Johnson is a Buy (May 21 - reuters) 4 Picks From Cramer's Dividend Stocks: Part II (May 20 - reuters) Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients (May 18 - reuters) Patients should consult before stopping Pfizer drug-FDA (May 17 - reuters) Novartis lung drug superior to placebo over 1 year (May 17 - reuters) Drug Fails: At Least It's Approved Already (May 17 - reuters) Pfizer drug shows promise in lung cancer-study (May 17 - reuters) Pfizer, Glaxo, J&J Grab ASCO Spotlight (May 17 - reuters) Why Jim Cramer Gives These 4 Dividend Stocks A Buy Rating (May 17 - reuters) Incyte's Potential Blockbuster Pipeline Asset Makes It An Attractive Takeover Target (May 16 - reuters) Amylin Goes A Little Wizard Of Oz On Shareholders (May 16 - reuters) Eli Lilly & Co Undervalued By Up To 30% (May 16 - reuters) Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) (May 16 - reuters) Lpath Back In Play (May 15 - reuters) Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting (May 14 - reuters) 4 Pharmaceuticals To Consider In A Highly Volatile Market (May 14 - reuters) Myrexis Undervalued As BioPharma Transforms (May 14 - reuters) Why Johnson & Johnson Looks Better Than Its Competitors (May 14 - reuters) 4 New Reasons To Be Bullish On Sanofi Now (May 13 - reuters) Pfizer Could Plummet Without Lipitor Replacement (May 12 - reuters) Sanofi Could Plummet On Imminent Plant Shutdown (May 12 - reuters) 5 Fantastic Healthcare Dividends For The Income Investor (May 12 - reuters) Investing In Big Pharma: What To Buy And What To Avoid (May 11 - reuters) Watson Has Double-Digit Upside, But Peers Are 'Strong Buys' (May 11 - reuters) Analysis And Valuation: J&J, Pfizer, Merck (May 10 - reuters) Isis: A Pick To Win The Biotech Derby (May 10 - reuters) FDA Recommendations Bode Well For Pfizer (May 10 - reuters) U.S. FDA advisers back Pfizer arthritis drug (May 09 - reuters) FDA Arthritis Advisory Committee Recommends Approval of Tofacitinib for Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (May 09 - reuters) Key Reasons why Johnson & Johnson is the Place to Be (May 09 - reuters) Biotech Hot Potato (May 09 - reuters) 5 Huge Reasons To Buy GlaxoSmithKline Now (May 09 - reuters) Bright Future Ahead Of Abbott Despite Mounting Competition (May 08 - reuters) Pfizer's Must-Win FDA Vote (May 08 - reuters) Johnson & Johnson Will Break $68 High In 2013 (May 08 - reuters) FDA staff question Pfizer arthritis drug benefits (May 07 - reuters) Start Small, Win Big (May 07 - reuters) UPDATE 1-FDA staff question Pfizer arthritis drug benefits (May 07 - reuters) FDA staff question Pfizer arthritis drug benefits (May 07 - reuters) Eli Lilly: This 4.7% Dividend Yielder Is A Strong 'Buy' Now (May 07 - reuters) Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ® (desvenlafaxine) 50 mg/day For The Treatment Of Major Depressive Disorder In Adults (May 07 - reuters) Pfizer: Alzheimer's Drugs Will Carry Stock To New Highs In 2013 (May 04 - reuters) Pfizer Beats Analyst Estimates on EPS (May 04 - reuters) Pfizer's Lyrica falls short in two pain studies (May 04 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY